Chemoradiotherapy with or without cetuximab in patients with oesophageal cancer (SCOPE1): a multicentre, phase 2/3 randomised trial (Q42596834)

3 November 2017

title

Chemoradiotherapy with or without cetuximab in patients with oesophageal cancer (SCOPE1): a multicentre, phase 2/3 randomised trial (English)

1 reference

multicenter clinical trial

3 November 2017

main subject

phase II clinical trial

0 references

0 references

chemoradiotherapy

0 references

phase III clinical trial

0 references

1 reference

11

1 reference

3 November 2017

12

1 reference

3 November 2017

Thomas Crosby

1

1 reference

3 November 2017

Christopher N Hurt

2

1 reference

3 November 2017

Stephen Falk

3

1 reference

3 November 2017

Simon Gollins

4

1 reference

3 November 2017

Somnath Mukherjee

5

1 reference

3 November 2017

John Staffurth

6

1 reference

3 November 2017

Ruby Ray

7

1 reference

3 November 2017

Nadim Bashir

8

1 reference

3 November 2017

John A Bridgewater

9

1 reference

3 November 2017

J Ian Geh

10

1 reference

3 November 2017

Rajarshi Roy

13

1 reference

3 November 2017

Tim Maughan

14

1 reference

3 November 2017

Gareth Griffiths

15

1 reference

3 November 2017

publication date

25 April 2013

1 reference

Lancet Oncology Commission

3 November 2017

published in

1 reference

3 November 2017

volume

14

1 reference

3 November 2017

issue

7

1 reference

3 November 2017

page(s)

627-637

1 reference

3 November 2017

cites work

Global cancer statistics

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970136-0

7 January 2021

Surgical resection with or without preoperative chemotherapy in oesophageal cancer: a randomised controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970136-0

7 January 2021

Perioperative chemotherapy compared with surgery alone for resectable gastroesophageal adenocarcinoma: an FNCLCC and FFCD multicenter phase III trial

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970136-0

7 January 2021

Chemoradiotherapy of locally advanced esophageal cancer: long-term follow-up of a prospective randomized trial (RTOG 85-01). Radiation Therapy Oncology Group

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970136-0

7 January 2021

Capecitabine and oxaliplatin for advanced esophagogastric cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970136-0

7 January 2021

Definitive chemoradiation in patients with inoperable oesophageal carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970136-0

7 January 2021

X-ray irradiation altered chemosensitivity of a p53-null non-small cell lung cancer cell line

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970136-0

7 January 2021

Pharmacologic requirements for obtaining sensitization of human tumor cells in vitro to combined 5-Fluorouracil or ftorafur and X rays.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970136-0

7 January 2021

Definitive Chemoradiation for Oesophageal Cancer — a Standard of Care in Patients with Non-metastatic Oesophageal Cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970136-0

7 January 2021

Expression of epidermal growth factor receptor in esophageal and esophagogastric junction adenocarcinomas: association with poor outcome

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970136-0

7 January 2021

Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970136-0

7 January 2021

Platinum-based chemotherapy plus cetuximab in head and neck cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970136-0

7 January 2021

Targeting the epidermal growth factor receptor in radiotherapy: radiobiological mechanisms, preclinical and clinical results

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970136-0

7 January 2021

Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970136-0

7 January 2021

SCOPE1: a randomised phase II/III multicentre clinical trial of definitive chemoradiation, with or without cetuximab, in carcinoma of the oesophagus

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970136-0

7 January 2021

Toward semi-automated assessment of target volume delineation in radiotherapy trials: the SCOPE 1 pretrial test case

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970136-0

7 January 2021

The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970136-0

7 January 2021

Clinical and psychometric validation of an EORTC questionnaire module, the EORTC QLQ-OES18, to assess quality of life in patients with oesophageal cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970136-0

7 January 2021

Combined modality radiotherapy and chemotherapy in nonsurgical management of localized carcinoma of the esophagus: a practice guideline.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970136-0

7 January 2021

Epirubicin, oxaliplatin, and capecitabine with or without panitumumab for patients with previously untreated advanced oesophagogastric cancer (REAL3): a randomised, open-label phase 3 trial

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970136-0

7 January 2021

Addition of cetuximab to oxaliplatin-based first-line combination chemotherapy for treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trial

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970136-0

7 January 2021

Capecitabine and cisplatin with or without cetuximab for patients with previously untreated advanced gastric cancer (EXPAND): a randomised, open-label phase 3 trial

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970136-0

7 January 2021

Cetuximab and chemoradiation for rectal cancer--is the water getting muddy?

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970136-0

7 January 2021

Modulation of cellular redox state underlies antagonism between oxaliplatin and cetuximab in human colorectal cancer cell lines

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970136-0

7 January 2021

Phase III trial of cetuximab with continuous or intermittent fluorouracil, leucovorin, and oxaliplatin (Nordic FLOX) versus FLOX alone in first-line treatment of metastatic colorectal cancer: the NORDIC-VII study

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970136-0

7 January 2021

Characterization of the timing and prevalence of receptor tyrosine kinase expression changes in oesophageal carcinogenesis.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970136-0

7 January 2021

A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970136-0

7 January 2021

Critical impact of radiotherapy protocol compliance and quality in the treatment of advanced head and neck cancer: results from TROG 02.02.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970136-0

7 January 2021

Utility of positron emission tomography for the staging of patients with potentially operable esophageal carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970136-0

7 January 2021

A prospective study to evaluate the impact of FDG-PET on CT-based radiotherapy treatment planning for oesophageal cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970136-0

7 January 2021

S0356: a phase II clinical and prospective molecular trial with oxaliplatin, fluorouracil, and external-beam radiation therapy before surgery for patients with esophageal adenocarcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970136-0

7 January 2021

Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970136-0

7 January 2021

Systematic overview of preoperative (neoadjuvant) chemoradiotherapy trials in oesophageal cancer: evidence of a radiation and chemotherapy dose response

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970136-0

7 January 2021

10.1016/S1470-2045(13)70136-0

Identifiers

DOI

1 reference

3 November 2017

1 reference